Retraction: Raf kinase inhibitor protein (RKIP) blocks signal transducer and activator of transcription 3 (STAT3) activation in breast and prostate cancer (PLoS ONE (2014) 9:3 (e92478) DOI: 10.1371/journal.pone.0092478);Raf Kinase Inhibitor Protein (RKIP) blocks Signal Transducer and Activator of Transcription 3 (STAT3) activation in breast and prostate cancer

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Yousuf, Saad ^a   Duan, MeiLi ^a,b   Moen, Erika L ^a   Cross Knorr, Sam ^a   Brilliant, Kate ^a   Bonavida, Benjamin ^c   LaValle, Theresa ^d   Yeung, Kam C ^e   Al Mulla, Fahd ^f   Chin, Eugene ^a   Chatterjee, Devasis ^a  

^a BROWN UNIVERSITY   (United States)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Kolltan Pharmaceuticals Inc ^*  (United States)

^e MEDICAL COLLEGE OF OHIO   (United States)

^f KUWAIT UNIVERSITY   (Kuwait)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHOXYESTRA 1,3,5(10),16 TETRAENE 3 CARBOXAMIDE; ANTINEOPLASTIC AGENT; INTERLEUKIN 6; JANUS KINASE 1; JANUS KINASE 2; MICROTUBULE INHIBITOR; MKC 1; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; PROTEIN KINASE P60; RAF PROTEIN; SERINE; STAT3 PROTEIN; TYROSINE; UNCLASSIFIED DRUG; 2-METHOXYOESTRA-1,3,5(10),16-TETRAENE-3-CARBOXAMIDE; ESTRANE DERIVATIVE; TUBULIN MODULATOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTOPHOSPHORYLATION; BREAST CANCER; CANCER CELL CULTURE; CELL STRAIN DU145; CELL STRAIN MDA 231; CELL STRAIN PC3; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; TRANSCRIPTION INITIATION; TUMOR GROWTH; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BREAST TUMOR; CANCER TRANSPLANTATION; CELL PROLIFERATION; DRUG EFFECTS; GENETIC TRANSFECTION; MALE; METABOLISM; PATHOPHYSIOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; ESTRENES; FEMALE; HUMANS; INTERLEUKIN-6; JANUS KINASE 1; MALE; MICE; NEOPLASM TRANSPLANTATION; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; PROSTATIC NEOPLASMS; STAT3 TRANSCRIPTION FACTOR; TRANSFECTION; TUBULIN MODULATORS;

EID: 84899071603     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0253350     Document Type: Erratum

References (76)

1. Clevenger CV (2004) Roles and regulation of stat family transcription factors in human breast cancer. Am J Pathol 165: 1449-1460.
2. Germain D, Frank DA (2007) Targeting the cytoplasmic and nuclear functions of signal transducers and activators of transcription 3 for cancer therapy. Clin Cancer Res 13: 5665-5669. (Pubitemid 47583890)
3. Darnell JE Jr. (2002) Transcription factors as targets for cancer therapy. Nat Rev Cancer 2: 740-749.
4. Heim MH (1999) The Jak-STAT pathway: cytokine signalling from the receptor to the nucleus. J Recept Signal Transduct Res 19: 75-120.
5. Yu H, Jove R (2004) The STATs of cancer-new molecular targets come of age. Nat Rev Cancer 4: 97-105. (Pubitemid 38198738)
6. Yuan ZL, Guan YJ, Chatterjee D, Chin YE (2005) Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science 307: 269-273. (Pubitemid 40116244)
7. Buettner R, Mora LB, Jove R (2002) Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 8: 945-954. (Pubitemid 35177340)
8. Constancio-Lund SS, Brabek J, Hanks SK (2009) Src transformation of colonic epithelial cells: enhanced anchorage-independent growth in an Apc(+/min) background. Mol Carcinog 48: 156-166.
9. Duhe RJ, Wang LH, Farrar WL (2001) Negative regulation of Janus kinases. Cell Biochem Biophys 34: 17-59. (Pubitemid 33703249)
10. Silver DL, Montell DJ (2001) Paracrine signaling through the JAK/STAT pathway activates invasive behavior of ovarian epithelial cells in Drosophila. Cell 107: 831-841. (Pubitemid 34084975)
11. Karni R, Jove R, Levitzki A (1999) Inhibition of pp60c-Src reduces Bcl-XL expression and reverses the transformed phenotype of cells overexpressing EGF and HER-2 receptors. Oncogene 18: 4654-4662. (Pubitemid 29417740)
12. Puthier D, Bataille R, Amiot M (1999) IL-6 up-regulates mcl-1 in human myeloma cells through JAK/STAT rather than ras/MAP kinase pathway. Eur J Immunol 29: 3945-3950.
13. Azare J, Leslie K, Al-Ahmadie H, Gerald W, Weinreb PH, et al. (2007) Constitutively activated Stat3 induces tumorigenesis and enhances cell motility of prostate epithelial cells through integrin beta 6. Mol Cell Biol 27: 4444-4453. (Pubitemid 46906567)
14. Dauer DJ, Ferraro B, Song L, Yu B, Mora L, et al. (2005) Stat3 regulates genes common to both wound healing and cancer. Oncogene 24: 3397-3408. (Pubitemid 40756241)
15. Ng DC, Lin BH, Lim CP, Huang G, Zhang T, et al. (2006) Stat3 regulates microtubules by antagonizing the depolymerization activity of stathmin. J Cell Biol 172: 245-257. (Pubitemid 43112971)
16. Alas S, Bonavida B (2003) Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis. Clin Cancer Res 9: 316-326. (Pubitemid 36109748)
17. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, et al. (1999) Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10: 105-115. (Pubitemid 29077388)
18. Darnowski JW, Goulette FA, Guan YJ, Chatterjee D, Yang ZF, et al. (2006) Stat3 cleavage by caspases: impact on full-length Stat3 expression, fragment formation, and transcriptional activity. J Biol Chem 281: 17707-17717. (Pubitemid 44035569)
19. Fernandes A, Hamburger AW, Gerwin BI (1999) ErbB-2 kinase is required for constitutive stat 3 activation in malignant human lung epithelial cells. Int J Cancer 83: 564-570. (Pubitemid 29489874)
20. Gao B, Shen X, Kunos G, Meng Q, Goldberg ID, et al. (2001) Constitutive activation of JAK-STAT3 signaling by BRCA1 in human prostate cancer cells. FEBS Lett 488: 179-184. (Pubitemid 32103593)
21. Garcia R, Bowman TL, Niu G, Yu H, Minton S, et al. (2001) Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 20: 2499-2513. (Pubitemid 32531347)
22. Lin TS, Mahajan S, Frank DA (2000) STAT signaling in the pathogenesis and treatment of leukemias. Oncogene 19: 2496-2504. (Pubitemid 30339205)
23. Rubin Grandis J, Zeng Q, Drenning SD (2000) Epidermal growth factor receptor-mediated stat3 signaling blocks apoptosis in head and neck cancer. Laryngoscope 110: 868-874. (Pubitemid 30266269)
24. Weber-Nordt RM, Egen C, Wehinger J, Ludwig W, Gouilleux-Gruart V, et al. (1996) Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines. Blood 88: 809-816. (Pubitemid 26333300)
25. Yeung K, Seitz T, Li S, Janosch P, McFerran B, et al. (1999) Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP. Nature 401: 173-177. (Pubitemid 29436321)
26. Yeung KC, Rose DW, Dhillon AS, Yaros D, Gustafsson M, et al. (2001) Raf kinase inhibitor protein interacts with NF-kappaB-inducing kinase and TAK1 and inhibits NF-kappaB activation. Mol Cell Biol 21: 7207-7217. (Pubitemid 32953475)
27. Slupsky JR, Quitterer U, Weber CK, Gierschik P, Lohse MJ, et al. (1999) Binding of Gbetagamma subunits to cRaf1 downregulates G-protein-coupled receptor signalling. Curr Biol 9: 971-974. (Pubitemid 29442483)
28. Al-Mulla F, Bitar MS, Al-Maghrebi M, Behbehani AI, Al-Ali W, et al. (2011) Raf kinase inhibitor protein RKIP enhances signaling by glycogen synthase kinase-3beta. Cancer Res 71: 1334-1343.
29. Chatterjee D, Bai Y, Wang Z, Beach S, Mott S, et al. (2004) RKIP sensitizes prostate and breast cancer cells to drug-induced apoptosis. J Biol Chem 279: 17515-17523. (Pubitemid 38560515)
30. Al-Mulla F, Hagan S, Behbehani AI, Bitar MS, George SS, et al. (2006) Raf kinase inhibitor protein expression in a survival analysis of colorectal cancer patients. J Clin Oncol 24: 5672-5679. (Pubitemid 46631308)
31. Fu Z, Smith PC, Zhang L, Rubin MA, Dunn RL, et al. (2003) Effects of raf kinase inhibitor protein expression on suppression of prostate cancer metastasis. J Natl Cancer Inst 95: 878-889. (Pubitemid 36833879)
32. Hagan S, Al-Mulla F, Mallon E, Oien K, Ferrier R, et al. (2005) Reduction of Raf-1 kinase inhibitor protein expression correlates with breast cancer metastasis. Clin Cancer Res 11: 7392-7397. (Pubitemid 41507699)
33. Keller ET, Fu Z, Yeung K, Brennan M (2004) Raf kinase inhibitor protein: a prostate cancer metastasis suppressor gene. Cancer Lett 207: 131-137. (Pubitemid 38457033)
34. Minoo P, Zlobec I, Baker K, Tornillo L, Terracciano L, et al. (2007) Loss of raf-1 kinase inhibitor protein expression is associated with tumor progression and metastasis in colorectal cancer. Am J Clin Pathol 127: 820-827.
35. Schuierer MM, Bataille F, Hagan S, Kolch W, Bosserhoff AK (2004) Reduction in Raf kinase inhibitor protein expression is associated with increased Ras-extracellular signal-regulated kinase signaling in melanoma cell lines. Cancer Res 64: 5186-5192. (Pubitemid 39006537)
36. Chatterjee D, Sabo E, Tavares R, Resnick MB (2008) Inverse association between Raf Kinase Inhibitory Protein and signal transducers and activators of transcription 3 expression in gastric adenocarcinoma patients: implications for clinical outcome. Clin Cancer Res 14: 2994-3001.
37. Beach S, Tang H, Park S, Dhillon AS, Keller ET, et al. (2008) Snail is a repressor of RKIP transcription in metastatic prostate cancer cells. Oncogene 27: 2243-2248. (Pubitemid 351483382)
38. Peinado H, Olmeda D, Cano A (2007) Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer 7: 415-428. (Pubitemid 46809165)
39. Sumantran VN, Ealovega MW, Nunez G, Clarke MF, Wicha MS (1995) Overexpression of Bcl-XS sensitizes MCF-7 cells to chemotherapy-induced apoptosis. Cancer Res 55: 2507-2510.
40. Haldar S, Chintapalli J, Croce CM (1996) Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 56: 1253-1255. (Pubitemid 26080965)
41. Chauhan D, Li G, Auclair D, Hideshima T, Richardson P, et al. (2003) Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays. Blood 101: 3606-3614. (Pubitemid 36857949)
42. Cushman M, He HM, Katzenellenbogen JA, Lin CM, Hamel E (1995) Synthesis, antitubulin and antimitotic activity, and cytotoxicity of analogs of 2-methoxyestradiol, an endogenous mammalian metabolite of estradiol that inhibits tubulin polymerization by binding to the colchicine binding site. J Med Chem 38: 2041-2049.
43. LaVallee TM, Burke PA, Swartz GM, Hamel E, Agoston GE, et al. (2008) Significant antitumor activity in vivo following treatment with the microtubule agent ENMD-1198. Mol Cancer Ther 7: 1472-1482.
44. LaVallee TM BP, Brokx R, Waters C, Chen X, Plum S, Fletcher G, Denny T, Fogler WE, Sidor CF, Bray MR (2007) MKC-1, A novel cell cycle inhibitor: Preclinical studies to support phase 2 clinical trial evaluation in non-small cell lung and pancreatic cancers. Proc Amer Assoc Cancer Res 48: 498.
45. Burke PA ZX, Kifle G, Chen X, Denny T, Fogler WE, Bengali K, Bray MR, LaVallee TM (2007) MKC-1 significantly increases survival of mice bearing renal cell carcinoma CAKI-1 xenograft tumors through inhibition of the Akt/mTOR pathway. AACR-NCI-EORTC Int Conf: B290.
46. Chatterjee D, Schmitz I, Krueger A, Yeung K, Kirchhoff S, et al. (2001) Induction of apoptosis in 9-nitrocamptothecin-treated DU145 human prostate carcinoma cells correlates with de novo synthesis of CD95 and CD95 ligand and down-regulation of c-FLIP(short). Cancer Res 61: 7148-7154. (Pubitemid 32946508)
47. Yu CL, Meyer DJ, Campbell GS, Larner AC, Carter-Su C, et al. (1995) Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science 269: 81-83.
48. Josic D, BrownMK, Huang F, CallananH, RucevicM, et al. (2005) Use of selective extraction and fast chromatographic separation combined with electrophoretic methods for mapping of membrane proteins. Electrophoresis 26: 2809-2822. (Pubitemid 41078990)
49. Clifton JG, Li X, Reutter W, Hixson DC, Josic D (2007) Comparative proteomics of rat liver and Morris hepatoma 7777 plasma membranes. J Chromatogr B Analyt Technol Biomed Life Sci 849: 293-301. (Pubitemid 46541714)
50. Lawson EL, Clifton JG, Huang F, Li X, Hixson DC, et al. (2006) Use of magnetic beads with immobilized monoclonal antibodies for isolation of highly pure plasma membranes. Electrophoresis 27: 2747-2758. (Pubitemid 44057524)
51. Shim JH, Park JY, Lee MG, Kang HH, Lee TR, et al. (2013) Human dermal stem/progenitor cell-derived conditioned medium ameliorates ultraviolet a-induced damage of normal human dermal fibroblasts. PLoS One 8: e67604.
52. Gao SP BJ (2006) Touched and moved by STAT3. Sci STKE: pe30.
53. Levy DE, Lee CK (2002) What does Stat3 do? J Clin Invest 109: 1143-1148. (Pubitemid 34496591)
54. Perez EA (1998) Paclitaxel in Breast Cancer. Oncologist 3: 373-389.
55. Speicher LA, Barone L, Tew KD (1992) Combined antimicrotubule activity of estramustine and taxol in human prostatic carcinoma cell lines. Cancer Res 52: 4433-4440.
56. Roth BJ, Yeap BY, Wilding G, Kasimis B, McLeod D, et al. (1993) Taxol in advanced, hormone-refractory carcinoma of the prostate. A phase II trial of the Eastern Cooperative Oncology Group. Cancer 72: 2457-2460. (Pubitemid 23299612)
57. Al-Mulla F, Bitar MS, Taqi Z, Yeung KC (2013) RKIP: Much more than Raf Kinase inhibitory protein. J Cell Physiol 228: 1688-1702.
58. Chatterjee D, Wyche JH, Pantazis P (1996) Induction of apoptosis in malignant and camptothecin-resistant human cells. Ann N Y Acad Sci 803: 143-156. (Pubitemid 27057981)
59. Barton BE, Karras JG, Murphy TF, Barton A, Huang HF (2004) Signal transducer and activator of transcription 3 (STAT3) activation in prostate cancer: Direct STAT3 inhibition induces apoptosis in prostate cancer lines. Mol Cancer Ther 3: 11-20. (Pubitemid 39193674)
60. al-Mulla F, Bitar MS, Taqi Z, Rath O, Kolch W (2011) RAF kinase inhibitory protein (RKIP) modulates cell cycle kinetics and motility.Mol Biosyst 7: 928-941.
61. Severin FF, Sorger PK, Hyman AA (1997) Kinetochores distinguish GTP from GDP forms of the microtubule lattice. Nature 388: 888-891.
62. Xie TX, Wei D, Liu M, Gao AC, Ali-Osman F, et al. (2004) Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene 23: 3550-3560. (Pubitemid 38658421)
63. Dolled-Filhart M, Camp RL, Kowalski DP, Smith BL, Rimm DL (2003) Tissue microarray analysis of signal transducers and activators of transcription 3 (Stat3) and phospho-Stat3 (Tyr705) in node-negative breast cancer shows nuclear localization is associated with a better prognosis. Clin Cancer Res 9: 594-600. (Pubitemid 36182589)
64. Watson CJ, Miller WR (1995) Elevated levels of members of the STAT family of transcription factors in breast carcinoma nuclear extracts. Br J Cancer 71: 840-844.
65. Iancu C, Mistry SJ, Arkin S, Atweh GF (2000) Taxol and anti-stathmin therapy: a synergistic combination that targets the mitotic spindle. Cancer Res 60: 3537-3541. (Pubitemid 30482174)
66. Eves EM, Shapiro P, Naik K, Klein UR, Trakul N, et al. (2006) Raf kinase inhibitory protein regulates aurora B kinase and the spindle checkpoint. Mol Cell 23: 561-574. (Pubitemid 44205493)
67. Finn RS (2008) Targeting Src in breast cancer. Ann Oncol 19: 1379-1386.
68. Yuan ZL, Guan YJ, Wang L, Wei W, Kane AB, et al. (2004) Central role of the threonine residue within the p+1 loop of receptor tyrosine kinase in STAT3 constitutive phosphorylation in metastatic cancer cells. Mol Cell Biol 24: 9390-9400. (Pubitemid 39391677)
69. Turkson J, Jove R (2000) STAT proteins: novel molecular targets for cancer drug discovery. Oncogene 19: 6613-6626. (Pubitemid 32197700)
70. Behera R, Kumar V, Lohite K, Karnik S, Kundu GC (2010) Activation of JAK2/STAT3 signaling by osteopontin promotes tumor growth in human breast cancer cells. Carcinogenesis 31: 192-200.
71. Burke WM, Jin X, Lin HJ, Huang M, Liu R, et al. (2001) Inhibition of constitutively active Stat3 suppresses growth of human ovarian and breast cancer cells. Oncogene 20: 7925-7934. (Pubitemid 34002969)
72. Blaskovich MA, Sun J, Cantor A, Turkson J, Jove R, et al. (2003) Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res 63: 1270-1279. (Pubitemid 36348705)
73. Turkson J, Kim JS, Zhang S, Yuan J, Huang M, et al. (2004) Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. Mol Cancer Ther 3: 261-269. (Pubitemid 39193701)
74. Deng J, Grande F, Neamati N (2007) Small molecule inhibitors of Stat3 signaling pathway. Curr Cancer Drug Targets 7: 91-107. (Pubitemid 46345511)
75. Nam S, Buettner R, Turkson J, Kim D, Cheng JQ, et al. (2005) Indirubin derivatives inhibit Stat3 signaling and induce apoptosis in human cancer cells. Proc Natl Acad Sci U S A 102: 5998-6003. (Pubitemid 40594244)
76. Berishaj M, Gao SP, Ahmed S, Leslie K, Al-Ahmadie H, et al. (2007) Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer. Breast Cancer Res 9: R32.